Polyrizon Retains Nasdaq Listing Following Hearings Panel
Polyrizon (Nasdaq: PLRZ) has successfully retained its Nasdaq listing following a hearing with the Nasdaq Hearings Panel. The company faced potential delisting concerns related to a private placement involving 5,962,073 ordinary shares, including 5,829,389 shares issued through warrant exercises. The Panel granted continued listing subject to meeting the Minimum Bid Price Rule by October 17, 2025.
Following the private placement, Polyrizon reports a cash balance of $15.68 million. The company has committed to avoiding complex financing instruments and is implementing enhanced internal controls for securities issuances and Nasdaq compliance.
Polyrizon (Nasdaq: PLRZ) ha mantenuto con successo la sua quotazione al Nasdaq dopo un'udienza con il Nasdaq Hearings Panel. La societ脿 ha affrontato potenziali rischi di esclusione legati a un collocamento privato che ha coinvolto 5.962.073 azioni ordinarie, di cui 5.829.389 azioni emesse tramite esercizio di warrant. Il Panel ha concesso la continuazione della quotazione a condizione che venga rispettata la Regola del Prezzo Minimo di Offerta entro il 17 ottobre 2025.
Dopo il collocamento privato, Polyrizon riporta un saldo di cassa di 15,68 milioni di dollari. La societ脿 si 猫 impegnata a evitare strumenti finanziari complessi e sta implementando controlli interni pi霉 rigorosi per le emissioni di titoli e la conformit脿 al Nasdaq.
Polyrizon (Nasdaq: PLRZ) ha mantenido con 茅xito su cotizaci贸n en Nasdaq tras una audiencia con el Nasdaq Hearings Panel. La empresa enfrentaba posibles preocupaciones de exclusi贸n relacionadas con una colocaci贸n privada que involucr贸 5.962.073 acciones ordinarias, incluyendo 5.829.389 acciones emitidas mediante el ejercicio de warrants. El Panel otorg贸 la continuidad de la cotizaci贸n bajo la condici贸n de cumplir con la Regla del Precio M铆nimo de Oferta antes del 17 de octubre de 2025.
Tras la colocaci贸n privada, Polyrizon reporta un saldo en efectivo de 15,68 millones de d贸lares. La compa帽铆a se ha comprometido a evitar instrumentos financieros complejos y est谩 implementando controles internos mejorados para la emisi贸n de valores y el cumplimiento con Nasdaq.
韽措Μ霛检澊歃� (Nasdaq: PLRZ)鞚�(電�) Nasdaq 觳須� 韺剱瓿检潣 鞁Μ 頉� 靹标车鞝侅溂搿� Nasdaq 靸侅灔 鞛愱博鞚� 鞙犾頄堨姷雼堧嫟. 須岇偓電� 5,962,073欤�鞚� 氤错喌欤检棎 甏�頃� 靷 氚滍枆瓿� 甏�霠悳 靸侅灔 韽愳 鞖半牑鞐� 歆侂┐頄堨溂氅�, 鞚� 欷� 5,829,389欤�電� 鞗岆煱韸� 頄夓偓搿� 氚滍枆霅橃棃鞀惦媹雼�. 韺剱鞚� 2025雲� 10鞗� 17鞚�旯岇 斓滌唽 鞛呾鞍臧� 攴滌爼鞚� 於╈”頃橂姅 臁瓣贝鞙茧 靸侅灔 歆�靻嶌潉 項堦皜頄堨姷雼堧嫟.
靷 氚滍枆 鞚错泟, 韽措Μ霛检澊歃岇潃 1,568毵� 雼煬鞚� 順勱笀 鞛旍暋鞚� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 氤奠灐頃� 旮堨湹 靸來拡鞚� 頂柬晿瓿� 歃濌秾 氚滍枆 氚� Nasdaq 攴滌爼 欷�靾橂ゼ 鞙勴暅 雮措秬 韱奠牅 臧曧檾鞐� 鞝勲厫頃橁碃 鞛堨姷雼堧嫟.
Polyrizon (Nasdaq : PLRZ) a r茅ussi 脿 conserver sa cotation au Nasdaq suite 脿 une audience devant le Nasdaq Hearings Panel. La soci茅t茅 faisait face 脿 des risques potentiels de radiation li茅s 脿 un placement priv茅 impliquant 5 962 073 actions ordinaires, dont 5 829 389 actions 茅mises via l'exercice de bons de souscription. Le Panel a accord茅 la poursuite de la cotation sous r茅serve de respecter la r猫gle du prix minimum d'offre d'ici le 17 octobre 2025.
脌 la suite du placement priv茅, Polyrizon annonce un solde de tr茅sorerie de 15,68 millions de dollars. La soci茅t茅 s'engage 脿 茅viter les instruments financiers complexes et met en place des contr么les internes renforc茅s pour les 茅missions de titres et la conformit茅 au Nasdaq.
Polyrizon (Nasdaq: PLRZ) hat nach einer Anh枚rung beim Nasdaq Hearings Panel erfolgreich seine Notierung am Nasdaq behalten. Das Unternehmen sah sich potenziellen Delisting-Bedenken aufgrund einer Privatplatzierung von 5.962.073 Stammaktien gegen眉ber, darunter 5.829.389 Aktien, die durch die Aus眉bung von Warrants ausgegeben wurden. Das Panel gew盲hrte die Fortsetzung der Notierung unter der Bedingung, die Mindestgebotspreisregel bis zum 17. Oktober 2025 einzuhalten.
Nach der Privatplatzierung meldet Polyrizon einen Bargeldbestand von 15,68 Millionen US-Dollar. Das Unternehmen hat sich verpflichtet, komplexe Finanzinstrumente zu vermeiden und verst盲rkte interne Kontrollen f眉r Wertpapieremissionen und die Einhaltung der Nasdaq-Regeln einzuf眉hren.
- Successfully retained Nasdaq listing following Panel hearing
- Strengthened cash position with $15.68 million balance
- All warrants from Private Placement have been exercised, simplifying capital structure
- Implementing new internal control framework for better compliance
- Must regain compliance with Minimum Bid Price Rule by October 17, 2025
- Significant dilution from issuance of 5,962,073 ordinary shares
- Previous compliance issues with Nasdaq listing requirements
Insights
Polyrizon avoided Nasdaq delisting following questionable financing practices but must maintain minimum bid requirements by October to retain listing.
Polyrizon has successfully retained its Nasdaq Capital Market listing following a regulatory challenge that threatened its public trading status. The company faced delisting due to concerns about a March 2025 private placement that included Series A warrants with an alternate cashless exercise provision 鈥� a financing structure Nasdaq viewed as potentially problematic under its public interest authority (Listing Rule 5101).
The securities issuance resulted in 5,962,073 ordinary shares being issued, with the vast majority (5,829,389 shares) coming from warrant exercises. This type of financing arrangement often raises regulatory concerns because alternate cashless exercise provisions can create unpredictable dilution and potentially circumvent certain market pricing protections.
While Polyrizon won its appeal to the Nasdaq Hearings Panel, this comes with strings attached 鈥� the company must regain compliance with the Minimum Bid Price Rule by October 17, 2025. This condition suggests the company's share price has fallen below $1, triggering another compliance issue that remains unresolved.
The company reports a cash position of $15.68 million following the private placement, and management highlighted that all warrants from the questioned financing have now been exercised, removing a source of potential future dilution. Additionally, Polyrizon is implementing governance improvements including formal controls over securities issuances and enhanced compliance monitoring 鈥� remedial steps typically expected by Nasdaq following listing rule violations.
Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the 鈥淐ompany鈥� or 鈥淧olyrizon鈥�), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Nasdaq Hearings Panel (the 鈥淧anel鈥�) granting the Company鈥檚 request for the continued listing of its securities on the Nasdaq Capital Market.
As previously reported by the Company on May 23, 2025, the Listing Qualifications Department of The Nasdaq Stock Market LLC (鈥淣asdaq鈥�) issued a public interest determination under Listing Rule 5101, citing the Company鈥檚 issuance of securities in a private placement (the 鈥淧rivate Placement鈥�) pursuant to the securities purchase agreement dated March 31, 2025, particularly the Series A warrants exercisable on an alternate cashless basis. In connection with the Private Placement, the Company issued an aggregate of 5,962,073 ordinary shares, which includes 5,829,389 ordinary shares issued upon the exercise of warrants on an alternate cashless basis. As of the date hereof, all of the warrants issued in the Private Placement have been exercised.
A hearing before the Panel was held on June 26, 2025. At the hearing, Polyrizon presented its plan to address Nasdaq鈥檚 concerns, including a commitment to avoid the use of overly complex or inherently dilutive financing instruments in future capital-raising activities.
On July 9, 2025, the Panel issued its determination, granting the Company's request for continued listing on the Nasdaq Capital Market, subject to the Company regaining compliance with the Minimum Bid Price Rule by October 17, 2025. 聽
鈥淲e appreciate Nasdaq鈥檚 thoughtful consideration of this matter and are pleased to maintain our listing on Nasdaq,鈥� said Tomer Izraeli, CEO of Polyrizon Ltd. 鈥淔ollowing the Private Placement, we have a cash balance of approximately
鈥淚n addition, we are implementing a formal internal control framework to govern future securities issuances and ensure ongoing compliance with Nasdaq listing standards,鈥� Mr. Izraeli added. 鈥淭his includes enhanced oversight of financing activity, Nasdaq-related reporting, and quarterly internal compliance reviews, which will be reported to our Audit Committee.鈥�
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon鈥檚 proprietary Capture and Contain聽TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a 鈥渂iological mask鈥� with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target 鈩�, or T&T. For more information, please visit聽.
Forward Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渆stimates鈥� and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company鈥檚 ability to continue to remain listed on Nasdaq. Forward-looking statements are not historical facts, and are based upon management鈥檚 current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management鈥檚 expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company鈥檚 reports filed from time to time with the Securities and Exchange Commission (鈥淪EC鈥�), including, but not limited to, the risks detailed in the Company鈥檚 annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC.. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
* Share amounts herein reflect the 1-for-250 reverse share split effected on May 27, 2025, as the Company announced in its Report on Form 6-K filed with the Securities and Exchange Commission on May 22, 2025.
Contacts:
Michal Efraty
Investor Relations
FAQ
Why was Polyrizon (PLRZ) at risk of losing its Nasdaq listing?
What conditions must Polyrizon (PLRZ) meet to maintain its Nasdaq listing?
How much cash does Polyrizon (PLRZ) have following the private placement?
What changes is Polyrizon (PLRZ) implementing to ensure future Nasdaq compliance?
How many shares were issued in Polyrizon's (PLRZ) private placement?
